1. Medicines
  2. Oncology
  3. SANDOSTATIN LAR (octreotide acetate)
  4. Resources

Prescribing information

 

Resources

   

In this section, you will find a collection of resources designed to support SANDOSTATIN® LAR® prescribers. This includes educational materials for HCPs as well as materials for your patients to help them better understand their condition and treatment.

Getting started for healthcare professionals

 

Image of the reconstitution and preparation guide.

Reconstitution and Preparation of SANDOSTATIN LAR

A guide for HCPs on how to prepare and administer SANDOSTATIN LAR.

Download

 
 

How to administer and prepare SANDOSTATIN LAR

A step-by-step video on how to prepare and administer SANDOSTATIN LAR.

 

Getting started for patients

 

Image of the guide to neuroendocrine tumours.

Guide to Neuroendocrine Tumours

A guide to neuroendocrine and its treatment – your questions answered.

Download

 

Image of the guide to acromegaly.

Guide to Acromegaly

A guide to acromegaly and its treatment - your questions answered.

Download

 
Rate this content: 
No votes yet
UK | May 2021 | 104733
Oncology
Resource
×

Ask Speakers

×

Medical Information Request

Top banner: Image of a doctor and patient facing each other, with a picture of the human intenstines on the wall behind them. Superimposed on top of the image is the drug name, "Sandostatin LAR octreotide acetate"

Efficacy

Show more

Rate this content: 
No votes yet
UK | May 2021 | 104728
Oncology
Article
Top banner: Image of a doctor and patient facing each other, with a picture of the human intenstines on the wall behind them. Superimposed on top of the image is the drug name, "Sandostatin LAR octreotide acetate" and the brand logo

Dosing and administration

Show more

Rate this content: 
No votes yet
UK | May 2021 | 104732
Oncology
Article
Top banner: Image of a doctor and patient facing each other, with a picture of the human intenstines on the wall behind them. Superimposed on top of the image is the drug name, "Sandostatin LAR octreotide acetate" and the brand logo

Safety profile

Show more

Rate this content: 
No votes yet
UK | May 2021 | 104734
Oncology
Article

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]